JP2020528878A - がん治療用インターフェロンプロドラッグ - Google Patents

がん治療用インターフェロンプロドラッグ Download PDF

Info

Publication number
JP2020528878A
JP2020528878A JP2019570445A JP2019570445A JP2020528878A JP 2020528878 A JP2020528878 A JP 2020528878A JP 2019570445 A JP2019570445 A JP 2019570445A JP 2019570445 A JP2019570445 A JP 2019570445A JP 2020528878 A JP2020528878 A JP 2020528878A
Authority
JP
Japan
Prior art keywords
ifn
cancer
interferon
nucleic acid
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019570445A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020528878A5 (cg-RX-API-DMAC10.html
Inventor
ヤン−チン フー
ヤン−チン フー
シュエジー カオ
シュエジー カオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
The University of Texas System
Original Assignee
The University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University of Texas System filed Critical The University of Texas System
Publication of JP2020528878A publication Critical patent/JP2020528878A/ja
Publication of JP2020528878A5 publication Critical patent/JP2020528878A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/565—IFN-beta
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2019570445A 2017-06-20 2018-06-18 がん治療用インターフェロンプロドラッグ Pending JP2020528878A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762522564P 2017-06-20 2017-06-20
US62/522,564 2017-06-20
PCT/US2018/037982 WO2018236701A1 (en) 2017-06-20 2018-06-18 INTERFERON PRODRUCE FOR THE TREATMENT OF CANCER

Publications (2)

Publication Number Publication Date
JP2020528878A true JP2020528878A (ja) 2020-10-01
JP2020528878A5 JP2020528878A5 (cg-RX-API-DMAC10.html) 2021-05-27

Family

ID=64737368

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019570445A Pending JP2020528878A (ja) 2017-06-20 2018-06-18 がん治療用インターフェロンプロドラッグ

Country Status (7)

Country Link
US (1) US20200123227A1 (cg-RX-API-DMAC10.html)
EP (1) EP3641829A4 (cg-RX-API-DMAC10.html)
JP (1) JP2020528878A (cg-RX-API-DMAC10.html)
KR (1) KR20200015742A (cg-RX-API-DMAC10.html)
CN (1) CN111050803A (cg-RX-API-DMAC10.html)
CA (1) CA3067539A1 (cg-RX-API-DMAC10.html)
WO (1) WO2018236701A1 (cg-RX-API-DMAC10.html)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511387A (ja) * 2021-03-16 2024-03-13 シートムエックス セラピューティクス,インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
JP2024523290A (ja) * 2021-06-18 2024-06-28 ナミ セラピューティクス, インコーポレイテッド がんの処置およびその方法における使用のための、マスクされたI型インターフェロン(IFNαおよびIFNβ)を含む融合タンパク質組成物

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210130430A1 (en) 2018-05-14 2021-05-06 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
MX2020012251A (es) 2018-05-14 2021-04-28 Werewolf Therapeutics Inc Polipeptidos de interleucina-2 activables y metodos de uso de los mismos.
WO2019222296A1 (en) 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
CA3136602A1 (en) 2019-04-15 2020-10-22 Qwixel Therapeutics Llc Fusion protein composition(s) comprising targeted masked type i interferons (ifna and ifnb) and an antibody against tumor antigen, for use in the treatment of cancer
BR112021022666A2 (pt) 2019-05-14 2022-03-29 Werewolf Therapeutics Inc Frações de separação e seus métodos e uso
CN114341189A (zh) 2019-06-12 2022-04-12 奥美药业有限公司 全新il-15前药及其应用
AU2020316002B2 (en) * 2019-07-25 2026-05-07 The University Of Chicago Compositions and methods comprising protease-activated therapeutic agents
BR112022009110A2 (pt) 2019-11-14 2022-07-26 Werewolf Therapeutics Inc Polipeptídeos de citocina ativáveis e métodos de uso destes
AU2021205981A1 (en) 2020-01-11 2022-07-14 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
US20240076355A1 (en) * 2021-01-14 2024-03-07 AskGene Pharma, Inc. Interferon Prodrugs and Methods of Making and Using the Same
EP4387987A2 (en) * 2021-08-18 2024-06-26 Werewolf Therapeutics, Inc. Activatable inteferon polypeptides and methods of use thereof
US20240400633A1 (en) * 2021-09-30 2024-12-05 Orionis Biosciences, Inc. Split human ifn-gamma and tnf-alpha constructs and uses thereof
WO2023060156A2 (en) * 2021-10-08 2023-04-13 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
MX2024004301A (es) * 2021-10-08 2024-04-26 Cytomx Therapeutics Inc Construcciones de citocinas activables y metodos combinados.
US20240067691A1 (en) * 2022-08-18 2024-02-29 Regeneron Pharmaceuticals, Inc. Interferon receptor agonists and uses thereof
WO2024186193A1 (ko) * 2023-03-08 2024-09-12 인제대학교 산학협력단 국소적 방사선 치료에서 전신성 항암 치료를 위한 조성물
KR20260026098A (ko) * 2023-05-12 2026-02-25 리제너론 파아마슈티컬스, 인크. 인터페론 수용체 길항제 및 이의 용도
EP4750813A1 (en) * 2023-07-25 2026-06-03 TJ Biopharma (Shanghai) Co., Ltd. Masked interferon fusion proteins and uses thereof
WO2025201363A1 (zh) * 2024-03-27 2025-10-02 高雄医学大学 细胞因子阻断抗体及其应用
WO2026158523A1 (en) * 2025-01-24 2026-07-30 Tj Biopharma (Hangzhou) Co., Ltd. Masked multifunctional proteins

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526242A (ja) * 1997-12-19 2001-12-18 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Ifnar2/ifn複合体
JP2010536370A (ja) * 2007-08-22 2010-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
JP2012520059A (ja) * 2009-02-23 2012-09-06 サイトムエックス セラピューティクス, インコーポレイテッド プロタンパク質およびその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040014652A1 (en) * 2000-06-01 2004-01-22 Andre Trouet Tumor activated prodrug compounds and methods of making and using the same
US20100189727A1 (en) * 2008-12-08 2010-07-29 Tegopharm Corporation Masking Ligands For Reversible Inhibition Of Multivalent Compounds
US11291721B2 (en) * 2016-03-21 2022-04-05 Marengo Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001526242A (ja) * 1997-12-19 2001-12-18 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ Ifnar2/ifn複合体
JP2010536370A (ja) * 2007-08-22 2010-12-02 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 活性化可能な結合ポリペプチドおよびその同定方法ならびに使用
JP2012520059A (ja) * 2009-02-23 2012-09-06 サイトムエックス セラピューティクス, インコーポレイテッド プロタンパク質およびその使用方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHEM. MED. CHEM., vol. 11, no. 22, JPN6023008478, 2016, pages 2474 - 2495, ISSN: 0005003375 *
ORAL MEDICINE, vol. 120, no. 5, JPN6022022241, 2015, pages 594 - 601, ISSN: 0004788935 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024511387A (ja) * 2021-03-16 2024-03-13 シートムエックス セラピューティクス,インコーポレイテッド マスクした活性化可能サイトカイン構成体ならびに関連する組成物及び方法
JP2024523290A (ja) * 2021-06-18 2024-06-28 ナミ セラピューティクス, インコーポレイテッド がんの処置およびその方法における使用のための、マスクされたI型インターフェロン(IFNαおよびIFNβ)を含む融合タンパク質組成物

Also Published As

Publication number Publication date
CA3067539A1 (en) 2018-12-27
RU2020101640A (ru) 2021-07-20
RU2020101640A3 (cg-RX-API-DMAC10.html) 2021-09-23
EP3641829A1 (en) 2020-04-29
US20200123227A1 (en) 2020-04-23
EP3641829A4 (en) 2021-04-21
KR20200015742A (ko) 2020-02-12
WO2018236701A1 (en) 2018-12-27
CN111050803A (zh) 2020-04-21

Similar Documents

Publication Publication Date Title
US20200123227A1 (en) Interferon prodrug for the treatment of cancer
US10479997B2 (en) Compositions and methods for diagnosis and treatment of prostate cancer
AU2013355379B2 (en) Immunotherapy with binding agents
CN102917721B (zh) Wnt拮抗剂和治疗与筛选方法
EP3202419A1 (en) Pvrig binding agents that modulate the hippo pathway and uses thereof
AU2019392915B2 (en) Identification and targeting of tumor promoting carcinoma associated fibroblasts for diagnosis and treatment of cancer and other diseases
EP4161967A2 (en) B7h3-targeting proteins and methods of use thereof
EA027502B1 (ru) Антитела против flt3 и способы их применения
EP3548071A1 (en) Methods for treatment of cancer comprising tigit-binding agents
US20230139944A1 (en) Targeting alpha3beta1 integrin for treatment of cancer and other diseases
WO2018148378A1 (en) Modulating biomarkers to increase tumor immunity and improve the efficiacy of cancer immunotherapy
EP3373968B1 (en) Glypican 2 as a cancer marker and therapeutic target
CN117979976A (zh) 靶向upar的car-t细胞及其用途
JP2021502329A (ja) Rhoaドミナントネガティブフォームを使用して癌を治療するための組成物および方法
ES2278731T3 (es) Proteinas denominadas fctrx y acidos nucleicos que las codifican.
US11976104B2 (en) TLR9 ligand trap
JP7599716B2 (ja) がんおよび他の疾患の診断および処置のための病原性細胞外マトリックスの同定および標的化
CN119143888A (zh) 一种融合蛋白及其制备方法与应用
RU2788736C2 (ru) Пролекарство интерферона для лечения рака
US20230366030A1 (en) Methods of detecting an inactivating mutation of pbrm1 in meningioma
WO2005070448A2 (en) Methods of use for secreted frizzled-related protein 3 (sfrp-3) in the prevention and treatment of disease
WO2025101551A1 (en) Prostate-specific membrane antigen (psma)-binding peptides and method of use
US20070274988A1 (en) Kiaa0779, Splice Variants Thereof, and Methods of Their Use
HK40112191A (en) Glypican 2 as a cancer marker and therapeutic target
WO2023150260A2 (en) Compounds that target tem8, compositions, and methods

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200117

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200221

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210121

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20210419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220601

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220831

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20230302